# Aqueous Humor Dynamic Components that Determine Intraocular Pressure Variance

> **NIH NIH R01** · OHIO STATE UNIVERSITY · 2020 · $546,507

## Abstract

Abstract
Randomized clinical trials (RCTs) show that reducing intraocular pressure (IOP) slows glaucoma progression.
Despite the clinician’s use of these RCTs, practice guidelines, and experience, patients still progress to
blindness. A gap in clinical science is our lack of knowledge on other risk factors that impact outcomes. Our
long-term goal is to improve outcomes by identifying biomarkers, behavioral and environmental factors, that
together profile a patient at risk for disease by age-of-onset, rate of progression, poor response to treatment,
and large IOP fluctuation. We focus on two IOP patterns that continue to confound the clinician’s ability to
provide consistent and effective IOP treatments: (1) IOP response to medications, ranging from non-responder
to super responder, and (2) IOP fluctuation, ranging from small to large, with the latter leading to progressive
visual field loss. Unfortunately, biomarkers that foretell these IOP patterns, which could improve clinical
decision-making have yet to be identified -- a critical barrier to the clinician identifying patients for whom
earlier or more aggressive treatment will mitigate glaucoma-related vision loss. The scientific premise is that
these mechanisms (i.e., aqueous flow, outflow facility, episcleral venous pressure, and calculated uveoscleral
flow) predict a patient’s IOP patterns. We will test the central hypothesis that variations in IOP response
to drugs and IOP fluctuation can be predicted by the aqueous humor dynamic (AHD) factors that
regulate IOP. We propose to test our hypothesis in 200 patients with ocular hypertension (OHT) or open-angle
glaucoma (OAG), as both conditions are investigated in drug trials for IOP drug response. There are two aims:
Aim 1. Test the hypothesis that AHD factors predict the IOP drug response. In Protocol 1, AHD factors
will be measured under baseline without treatment, and after a randomized order of 1-week treatments with
timolol 0.5% followed by a washout period and then latanoprost 0.005% or vice versa. Aim 2. Test the
hypothesis that aqueous flow and outflow facility predict IOP fluctuation. In Protocol 2, IOP fluctuation
will be measured in the non-clinic setting using the Icare® Home tonometer over multiple days at baseline and
under monotherapy treatment during Protocol 1. Clinical Impact: Our approach to apply AHD methods to
understand variation in drug response and IOP fluctuation is innovative. We predict that AHD factors will
explain drug response and IOP fluctuation. Tying-down these relationships will provide new knowledge that will
form the basis of future phenotype-genotype studies to identify genetic risk alleles of drug response and IOP
fluctuation, resulting in an integrated risk score combining clinical and genetic risk profiles for drug response
and IOP fluctuation. The ability to determine which patient needs earlier and more aggressive treatment will
ultimately lead to more efficient medical management with fewer follow-up o...

## Key facts

- **NIH application ID:** 10004052
- **Project number:** 7R01EY022124-06
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Sayoko E Moroi
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $546,507
- **Award type:** 7
- **Project period:** 2012-03-03 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10004052

## Citation

> US National Institutes of Health, RePORTER application 10004052, Aqueous Humor Dynamic Components that Determine Intraocular Pressure Variance (7R01EY022124-06). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10004052. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*